BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Performance Pay Package Halved for GlaxoSmithKline (GSK) CEO


3/7/2013 8:24:57 AM

Sir Andrew Witty, the boss of Britain’s biggest drugmaker, saw his total remuneration drop by almost half last year, as declining company sales in Europe affected his performance-based pay. The chief executive of GlaxoSmithKline saw his total pay packet cut from £6.8m in 2011 to £3.9m last year, the company said in its annual report published yesterday. Of the total pay packet, £1.03m was his base salary, up 3pc from the previous year. A further £49,000 was paid out as “other benefits”, such as healthcare, a company car or personal financial advice. But his pay based on performance – accounting for 72pc of his overall remuneration in 2012 – suffered significantly due largely to sales falling in the austerity-hit eurozone. Of his total pay, Sir Andrew’s annual bonus was £905,000, down from £2m in 2011. He also earned a further £125,000 as part of a deferred bonus plan. His performance share plan fell by more than half to £1.78m.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES